Company Profile
Dong-A ST develops, manufactures, and markets pharmaceutical products in South Korea and globally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy.
Its portfolio also includes Closerin Cap for active pulmonary and extra-pulmonary tuberculosis, Eporon inj./PFS for anemia associated with chronic renal failure, and Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers.
Its portfolio also includes Gonadopin inj./PFS for ovarian hyperstimulation and anovulation, Growtropin II Inj./AQ /cartridge to treat growth failure due to an inadequate secretion of growth hormone and idiopathic short stature, small for gestational age, turner syndrome, and Leucostim Inj. for neutropenia in patients receiving myelosuppressive chemotherapy
Mainta inj. for non-small cell lung cancer and malignant pleural mesothelioma; Monotaxel inj. to treat breast, non-small cell lung, prostate, head, and neck cancers, as well as gastric adenocarcinoma Motilitone tab. for use in functional dyspepsia treatment; Stillen tab/ Stillen 2X tab. to treat gastritis
Suganon tab./Sugamet XR tab. and Sugadapa tab./Sugatree XR tab for type 2 diabetes mellitus. Its portfolio also includes DA-3880 PFS to treat renal anemia and darbepoetin-alfa, and Zydena tab. for erectile dysfunction treatment, as well as licensed-in and licensed-out drugs
Medical devices, which cover high-technology medical devices, custom-made products, and sets of artificial cardiac circuits for use in open-heart surgery. Founded in 1932, Dong-A ST is headquartered in Seoul, South Korea.